さあ, 日本人たちは参考しなさい.

KO 255 tyrel 2,811,753

2020-02-23 01:40

1. 実験的な抗ウイルス薬剤

2. RNA ウイルスに対応して RNA 重合酵素を選択的に抑制

3. influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus, flaviviruses, arenaviruses, bunyaviruses and alphavirusesに活性化になる

4. RNA ウイルスに対して生存ドル可能な表現型で転換突然変異を誘導する

5. 哺乳類細胞の RNAや DNA 合成を抑制しなくて, 哺乳類細胞に毒性がない

6. 2014年に日本でインフルエンザ対応目的に備蓄が承認される

7. 人間の主要祈祷細胞に対しては效能を見せてくれなくてインフルエンザ治療に対しては效果があるのか疑心される

8. 鼠エボラウイルスに対しては效能を見せてくれるが, 人間エボラウイルスに対しては效能が証明されない.

9. フランスでこの薬を飲んでエボラウイルスから治ったという報告があって, 他の国々でも血中私‾中農島のエボラウイルスによる致死率を低めてくれたと報告される. 高濃度のエボラウイルスに対しては效果がなし

10. 現在ウハンコロナバイロスにも使用中

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95-102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446-54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.

Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLoS Neglected Tropical Diseases. 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.

Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208-211. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.

Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253-61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.

Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410-1414. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.

Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5"-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.

Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology. 87 (7): 3741-51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (March 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLoS Medicine. 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.

Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741-6. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.

Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". Molecular Pharmacology. 84 (4): 615-29. doi:10.1124/mol.113.087247. PMID 23907213.

Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766-18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.

Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619-24. doi:10.1099/vir.0.067199-0. PMID 24795448.

Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17-21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.

原文を見る

자, 일본인들은 참고해라.

1. 실험적인 항바이러스 약제

2. RNA 바이러스에 대응해서 RNA 중합효소를 선택적으로 억제

3. influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus, flaviviruses, arenaviruses, bunyaviruses and alphaviruses에 활성화됨

4. RNA 바이러스에 대해서 생존불가능한 표현형으로 전환 돌연변이를 유도함

5. 포유류 세포의 RNA나 DNA 합성을 억제하지는 않고, 포유류 세포에 독성이 있지는 않음

6. 2014년에 일본에서 인플루엔자 대응 목적으로 비축이 승인됨

7. 인간의 주요 기도세포에 대하여는 효능을 보여주지 않아서 인플루엔자 치료에 대해서는 효과가 있는지 의심됨

8. 쥐 에볼라 바이러스에 대해서는 효능을 보여주지만, 인간 에볼라 바이러스에 대해서는 효능이 증명되지 않음.

9. 프랑스에서 이 약을 먹고 에볼라 바이러스로부터 치료되었다는 보고가 있고, 다른 국가들에서도 혈중 저~중농도의 에볼라 바이러스에 의한 치사율을 낮춰주었다고 보고됨. 고농도의 에볼라 바이러스에 대해서는 효과가 없음

10. 현재 우한코로나바이러스에도 사용 중

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.

Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208–211. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.

Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.

Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.

Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology. 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.

Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741–6. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.

Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.

Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.

Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.

いいね・コメントにはログインが必要です。

コメント ( 5 )

さあ, 日本人たちは参考しなさい.

자, 일본인들은 참고해라.

投稿一覧